DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-351/SLR 002 **Approval Letter**

Watson Laboratories, Inc.
Attention: Lawrence Ventura, D.V.M., M.B.A.
Associate Director, Regulatory Liaison
Regulatory Affairs
577 Chipeta Way
Salt Lake City, UT 84108

Dear Dr. Ventura:

Please refer to your supplemental new drug applications dated December 19, 2005, received December 20, 2005, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Oxytrol transdermal system (oxybutynin chloride, 3.9 mg/day).

We acknowledge receipt of your submission dated May 31, 2006. This submission constituted a complete response to our May 9, 2006, Approvable letter.

This Changes Being Effected (CBE) supplemental new drug application, as amended, provides for the proposed addition of "dizziness" to the PRECAUTIONS and ADVERSE EVENTS, *Postmarketing Surveillance* sections of the package insert (PI) and the proposed addition of "dizziness" to the Patient Information Insert for Oxytrol transdermal system.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert and text for the patient information insert).

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA.* Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved supplement NDA 21-351/S002**." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
WO 22, Room 4447
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Jean Makie, Sr. Regulatory Project Manager, at 301-796-0952.

Sincerely,

{See appended electronic signature page}

Scott Monroe, M.D.
Acting Director
Division of Reproductive and Urologic Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosure

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Scott Monroe

7/5/2006 04:24:50 PM